Want to see CSTL full AI Analyst Report?
CSTL Stock Chart & Stats
$25.05
-$0.86(-2.67%)
At close: 4:00 PM EST
$25.05
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $44.28
Previous CloseN/A
Volume108.23K
Average Volume (3M)350.42K
Market Cap
$744.90M
Enterprise Value$587.14M
Total Cash (Recent Filing)$261.69M
Total Debt (Recent Filing)$36.72M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Jul 30, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding30,329,952
10 Day Avg. Volume333,174
30 Day Avg. Volume350,424
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue1.73
Enterprise Value/Gross Profit2.24
Enterprise Value/Ebitda-809.10
Forecast
1Y Price Target
$42.43Price Target Upside69.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.45
Revenue Forecast (FY)$352.75M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity & Low LeverageA cash and marketable securities balance of ~$261.7M plus a low debt-to-equity (<0.08) provides durable runway to fund commercialization, evidence generation, capacity buildouts or selective M&A without immediate financing. This liquidity cushions reimbursement timing risks and supports multi-year growth plans.
Robust Core Volume GrowthSustained double-digit volume growth across core assays (DecisionDx‑Melanoma, TissueCypher) indicates strong clinical adoption and referral patterns. Durable test demand expands recurring service revenue, improves operational leverage as labs scale, and strengthens the company's position in precision diagnostics over multiple quarters.
Positive Operating Cash Flow & Historical ScalingOperating cash flow turning positive (~$48M TTM) alongside multi-year revenue scaling demonstrates the business model converts test volume into cash. This durable cash-generation trend underpins reinvestment capacity and reduces reliance on external capital as the company navigates reimbursement and commercialization cycles.
Bears Say
Reimbursement Uncertainty (DecisionDx‑SCC / Advanced ADTx)Unresolved Medicare contractor decisions and pending reimbursement for DecisionDx‑SCC and Advanced ADTx create structural revenue timing risk. Payer coverage affects realized price and adoption; delays can postpone clinician uptake, depress near-term realizations per test, and increase collection and appeals costs over multiple quarters.
Profitability Still Negative And VolatilePersistent adjusted EBITDA deficits and reversion to net losses indicate profitability remains fragile. Until scaled margins and payer mix stabilize, the company may burn cash during growth investments, limiting discretionary spending and increasing sensitivity to slower test volume or reimbursement setbacks over the next several quarters.
Margin Compression & Rising Operating CostsCompression in adjusted gross margin and rising SG&A, R&D and lab costs reflect higher per-test costs and capacity investments. These structural cost pressures, plus weaker free cash flow conversion, can limit long-term margin sustainability unless productivity or pricing improves, constraining durable operating leverage.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $744.90M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on May 06, 2026. The company reported -$0.49 earnings per share for the quarter, the consensus estimate of -$0.49 by $0.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.4.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 30,329,952 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.49 in its last earnings report, expectations of -$0.49. Following the earnings report the stock price went down -22.263%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.43 (69.38% Upside)
$42.43 (69.38% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 205.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.06%
12-Months-Change
Fundamentals
Return on Equity
-2.77%
Trailing 12-Months
Asset Growth
9.19%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum across core products—notably DecisionDx‑Melanoma and TissueCypher—with significant year‑over‑year test volume growth (36% core volumes; 58% TissueCypher) and an uplifted full‑year revenue guide. Profitability metrics improved versus prior year (narrower net loss, improved adjusted EBITDA) and the balance sheet remains solid with ~$261.7M in cash and marketable securities. Key negatives are an adjusted gross margin decline versus the prior comparable period, continued negative adjusted EBITDA (albeit improved), operating cash use in Q1, ongoing reimbursement and timing uncertainty for DecisionDx‑SCC and for broad commercialization of Advanced ADTx, and higher operating costs tied to growth and capacity investments. On balance, the positive commercial traction, raised guidance, improving profitability trends, and healthy liquidity outweigh the remaining execution and reimbursement risks.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$42.43
▲(69.38% Upside)
Technical Analysis
Ownership Overview
2.53% Insiders
16.30% Mutual Funds
1.02% Other Institutional Investors
65.37% Public Companies and
Individual Investors